- Home
- PAYO vs EVO Comparison
PAYO vs EVO Comparison
Compare PAYO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- EVO
- Stock Information
- Founded
- PAYO 2005
- EVO 1993
- Country
- PAYO United States
- EVO Germany
- Employees
- PAYO N/A
- EVO N/A
- Industry
- PAYO EDP Services
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- EVO Health Care
- Exchange
- PAYO Nasdaq
- EVO Nasdaq
- Market Cap
- PAYO 2.5B
- EVO 1.8B
- IPO Year
- PAYO N/A
- EVO 2021
- Fundamental
- Price
- PAYO $7.02
- EVO $3.36
- Analyst Decision
- PAYO Strong Buy
- EVO Strong Buy
- Analyst Count
- PAYO 6
- EVO 1
- Target Price
- PAYO $8.25
- EVO $8.00
- AVG Volume (30 Days)
- PAYO 3.0M
- EVO 109.4K
- Earning Date
- PAYO 08-07-2024
- EVO 11-06-2024
- Dividend Yield
- PAYO N/A
- EVO N/A
- EPS Growth
- PAYO 447.53
- EVO N/A
- EPS
- PAYO 0.26
- EVO N/A
- Revenue
- PAYO $900,058,000.00
- EVO $844,788,385.00
- Revenue This Year
- PAYO $14.05
- EVO $8.39
- Revenue Next Year
- PAYO $7.61
- EVO $14.55
- P/E Ratio
- PAYO $27.13
- EVO N/A
- Revenue Growth
- PAYO 21.43
- EVO N/A
- 52 Week Low
- PAYO $4.22
- EVO $2.85
- 52 Week High
- PAYO $7.57
- EVO $12.40
- Technical
- Relative Strength Index (RSI)
- PAYO 58.07
- EVO 42.55
- Support Level
- PAYO $7.02
- EVO $3.29
- Resistance Level
- PAYO $7.57
- EVO $3.49
- Average True Range (ATR)
- PAYO 0.19
- EVO 0.10
- MACD
- PAYO -0.06
- EVO 0.05
- Stochastic Oscillator
- PAYO 20.29
- EVO 36.36
About PAYO Payoneer Global Inc.
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started to empower global commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.